We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Trillium Therapeutics Inc | NASDAQ:TRIL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 18.44 | 20.33 | 18.30 | 0 | 01:00:00 |
The results of the director elections were as follows:
Name | Votes inFavor | % Votes inFavor | VotesWithheld | % VotesWithheld |
Mr. Luke Beshar | 45,690,551 | 89.6 | 5,331,299 | 10.4 |
Dr. Michael Kamarck | 50,875,937 | 99.7 | 145,912 | 0.3 |
Mr. Scott Myers | 50,879,347 | 99.7 | 142,503 | 0.3 |
Mr. Paolo Pucci | 50,842,785 | 99.7 | 179,065 | 0.3 |
Dr. Jan Skvarka | 50,903,051 | 99.8 | 118,798 | 0.2 |
Dr. Helen Tayton-Martin | 50,766,458 | 99.5 | 255,391 | 0.5 |
Mr. Paul Walker | 41,737,821 | 81.8 | 9,284,029 | 18.2 |
The shareholders of the Corporation also voted to reappoint Ernst & Young LLP, Chartered Professional Accountants, Licensed Public Accountants as auditors of the Corporation for the ensuing year. In addition, the shareholders approved the non-binding, advisory vote on the compensation paid to the Corporation’s named executive officers and recommended that future advisory votes on the compensation paid to the Corporation’s named executive officers should be held every year. For complete voting results on all matters approved at the Meeting, please see the Corporation’s Report of Voting Results dated June 9, 2021 available on SEDAR at www.sedar.com and the Current Report on Form 8-K filed on EDGAR.
About Trillium Therapeutics Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-622 and TTI-621, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system.
For more information visit: www.trilliumtherapeutics.com
Company Contact:Rosemary HarrisonSVP, Corporate Development and StrategyTrillium Therapeutics Inc. 416-595-0627 x225investors@trilliumtherapeutics.comwww.trilliumtherapeutics.com
Media Relations:Mike BeyerSam Brown Inc.312-961-2502mikebeyer@sambrown.com
1 Year Trillium Therapeutics Chart |
1 Month Trillium Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions